聖濟堂(600227.SH):控股子公司收到中檢院頒發的胎盤羊膜間充質幹細胞《檢驗報告》
格隆匯4月21日丨聖濟堂(600227.SH)公佈,2020年4月21日,公司控股子公司貴州中觀生物技術有限公司(“中觀生物”)收到中國食品藥品檢定研究院(“中檢院”)頒發的胎盤羊膜間充質幹細胞《檢驗報告》。中檢院是國家檢驗藥品生物製品質量的法定機構和最高技術仲裁機構,具有實驗室認可(CNAS)和資質認定(CMA)資格的國家級檢定實驗室。這是中觀生物送檢的第一批次胎盤羊膜間充質幹細胞樣品,分別為人胎盤羊膜間充質幹細胞(hAMSC-068)第5代(P5)和第10代(P10)。
檢品名稱:胎盤羊膜間充質幹細胞;檢驗結論:細胞形態、細胞株鑑別、細胞表面抗原分析、細胞乾性標誌、細胞特定分化情況以及免疫調控功能均符合胎盤羊膜間充質幹細胞特性。
無菌檢驗、支原體檢驗、外源病毒檢驗、逆轉錄病毒檢驗均符合陰性。
成瘤性檢查無克隆反應、無致瘤作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.